Topical moxifloxacin was well absorbed. Maximum moxifloxacin concentrations were approximately 30 times higher than the median MICs for common pathogens in bacterial endophthalmitis, indicating that either regimen may provide sufficient concentrations to prevent postoperative endophthalmitis.

BACKGROUND AND OBJECTIVE: Clinical trials in neovascular age-related macular degeneration (nAMD) demonstrate that high visual acuity (VA) can be maintained, and low VA can be improved with anti-vascular endothelial growth factor (VEGF) treatment. Few real-world data investigating the relationship between baseline VA and long-term outcomes exist. This study compares VA at diagnosis and after treatment using data from a large patient registry. PATIENTS AND METHODS: Retrospective study of IRIS Registry patients diagnosed with nAMD in one or both eyes between January 2013 and June 2017. Patients received at least two anti-VEGF injections in the study eye(s) less than 45 days apart during the study period. Primary outcomes were the percentage of eyes with 20/40 VA or better at diagnosis and association of VA at diagnosis with longer-term visual outcomes. RESULTS: The study included 162,902 eyes. Among all included eyes, 34.3% presented with 20/40 VA or better at diagnosis. Patients with 20/40 vision or better at baseline maintained a mean VA of 20/40 or better for 2 years after treatment initiation. CONCLUSIONS: Baseline VA at nAMD diagnosis predicts long-term VA outcomes. Early diagnosis before VA is adversely affected is a key factor in preserving vision in patients with nAMD. [ Ophthalmic Surg Lasers Imaging Retina . 2020;51:633–639.]

Once daily topical ocular administration of LUMIGAN or TRAVATAN for 3 weeks resulted in significant concentrations of BFA and TFA in the AH. Quantifiable levels of bimatoprost amide were also measured. Maximum concentrations of BFA (30.9 nM) and TFA (3.91 nM) in the anterior chamber are sufficient to fully activate the FP prostanoid receptors in the target cells of the ciliary muscle and trabecular meshwork. Both bimatoprost in LUMIGAN and travoprost in TRAVATAN are essentially prodrugs that are rapidly hydrolyzed to their respective free acids that induce the IOP-lowering effect observed with both drugs in vivo.

Objectives: To evaluate the impact of dry eye disease (DED) on health-related quality of life, work productivity, daily activities, and healthcare resource use. MethOds: Data were analyzed from participants (≥ 18 years) of the 2013 National Health and Wellness Survey. Participants were classified as: Diagnosed-DED, Symptomatic-Undiagnosed (undiagnosed but experienced DED symptoms), and Non-DED (no DED diagnosis/symptoms). Outcome measures included: the Short Form (SF)-36 health survey (mental component summary [MCS], physical component summary [PCS]; 0-100 scale, higher= better health status), Work Productivity and Activity Impairment (WPAI) questionnaire (absenteeism, presenteeism, impairment in daily activities in past 7 days), and healthcare resource use. Multivariate regression was used to estimate adjusted group effects relative to the Non-DED group for each outcome, controlling for age, sex, insurance type, socio-demographic and lifestyle factors, and comorbidities. Results: There were a total of 74,095 participants (mean age 48 years (SD 17), 52% women): 5,042 Diagnosed-DED, 1,785 Symptomatic-Undiagnosed, and 67,268 Non-DED. For each measure, Diagnosed-DED and Symptomatic-Undiagnosed participants had significantly worse outcomes than the Non-DED group (P< 0.001 for all comparisons). For the Diagnosed-DED, Symptomatic-Undiagnosed, and Non-DED groups, mean (SD) scores for the SF-36

No abstract